Shekita Green (USA) is living with neuromyelitis optica spectrum disorder (NMOSD) and joins us for Rare Disease Day to share her experiences. She discusses her initial symptoms, the journey to diagnosis and her current treatment regimen. Shekita also talks about the strategies she uses to reduce the impact of NMOSD on her day-to-day life.
Touch Medical Media is supporting Rare Disease Day (28 February 2022) to shine a light on healthcare inequalities for people living with rare diseases, focusing on patient quality of life and the difficulty of diagnosing patients early.
- What symptoms marked the beginning of your journey with NMOSD, and when did you get your diagnosis? (0:14)
- How has living with NMOSD affected your life and what support is important to you? (1:13)
- Does your current treatment regimen allow you to aim for a ‘normality’ of life and how do you cope with relapses? (2:32)
Disclosures: Shekita Green has nothing to disclose in relation to this video.
Support: The production of this video was supported by Touch Medical Media.
Other content available in support of Rare Disease Day includes:
- Jackie Palace: Improving diagnosis and treatment of neuromyelitis optica spectrum disorder
- Said Beydoun: Understanding myasthenia gravis and the impact on patients’ quality of life
- Megan Hunter: Living with myasthenia gravis – A journey to diagnosis
- Damara Ortiz: The impact of Pompe disease and the importance of newborn screening
- Ethan Crough: Living with achondroplasia – Celebrating diversity and increasing awareness
- Spero R Cataland: Acquired thrombotic thrombocytopenic purpura – Risks, complications and the impact on daily life
- Richard Keen, Rare Disease Day 2022: Rare bone diseases – Diagnosis, management and patient quality of life
Share this Video
Related Videos In Neuromyelitis Optica Spectrum Disorder
Sean Pittock, ECTRIMS 2022: Subgroup analyses from the phase 3 CHAMPION-NMOSD investigating ravulizumab for neuromyelitis optica spectrum disorder
The CHAMPION-NMOSD trial (NCT04201262) is a global, open-label, multicentre, phase 3, externally controlled study of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD). In this touchNEUROLOGY interview, we caught up with Prof. Sean Pittock (Mayo Clinic, Rochester, MN, USA) to discuss the pre-specified efficacy analyses in clinically relevant patient subgroups, and the […]
Sean Pittock, ECTRIMS 2022: Phase 3 CHAMPION-NMOSD trial results – Ravulizumab in the treatment of AQP4-IgG neuromyelitis optica spectrum disorder
The CHAMPION-NMOSD trial (NCT04201262) is a global, open-label, multicentre, phase 3, externally controlled study of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD). In this touchNEUROLOGY interview, we caught up with Prof. Sean Pittock (Mayo Clinic, Rochester, MN, USA) to discuss the unmet needs in the treatment and management of NMOSD, and […]
Jeffrey Bennett, AAN 2022: Challenges in the treatment of aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder
Aquaporin 4-immunoglobulin G (AQP4-IgG) plays a major role in the pathogenesis of neuromyelitis optica spectrum disorder (NMOSD). Prof. Jeffrey Bennett (University of Colorado School of Medicine, Aurora, CO, USA) discusses the challenges in the treatment of NMOSD. Questions: What are the challenges in the treatment of neuromyelitis optica spectrum disorder (NMOSD)? (0:14) What is the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!